CRISPR Therapeutics CRSP Cash Flow Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| -$581.6M-58.8% | -$366.25M— | —— | -$650.18M— | ||
| $19.48M+1.1% | $19.26M-2.9% | $19.84M-17.9% | $24.17M+34.6% | ||
| $72.5M-16.3% | $86.57M+6.8% | $81.03M-17.3% | $97.95M-4.3% | ||
| -$345.01M-142% | -$142.77M+45.2% | -$260.38M+47.5% | -$495.74M— | ||
| $914K-51.9% | $1.9M-79.9% | $9.47M-74.5% | $37.19M-54.5% | ||
| —— | —— | —— | —— | ||
| $426.03M+28.1% | $332.45M+431% | $62.66M+62.4% | $38.59M-84.6% | ||
| $49.3M— | —— | —— | -$715.88M-192% | ||
| -$345.93M-139% | -$144.68M+46.4% | -$269.85M+49.4% | -$532.93M— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does CRISPR Therapeutics generate?
- CRISPR Therapeutics (CRSP) generated -$400.0M in operating cash flow over the trailing twelve months.
- What is CRISPR Therapeutics's free cash flow?
- After $1.2M of capital expenditures, CRISPR Therapeutics's free cash flow was -$401.2M over the trailing twelve months, down 30.3% year over year.
- Where does CRISPR Therapeutics's cash flow data come from?
- Every line is extracted from CRISPR Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
